Polymyalgia Rheumatica Trial, Recruiting NCT07001059 Sponsor: Hôpital NOVO Condition: Polymyalgia Rheumatica
Back to Polymyalgia Rheumatica

Polymyalgia Rheumatica Trial, Recruiting

NCT07001059
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are suspected to have a condition called GCA (Giant Cell Arteritis), meaning your doctor thinks you may have it but it has not been confirmed yet
  • You are over 50 years old

Who may not be able to join:

  • You have previously been diagnosed with GCA (Giant Cell Arteritis)
  • You have a history of a condition called polymyalgia rheumatica (a disorder causing muscle pain and stiffness) and did not have a specific type of full-body scan called a PET scan at the time of your diagnosis
  • You have a history of retinal disease (a condition affecting the back of the eye), a condition affecting the nerves in the brain or spinal cord, or a condition where pressure inside your skull is too high
  • You have taken high-dose steroid medication (corticosteroids above 0.5mg/kg) at any point in the last 2 weeks

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Omar AL TABAA, Dr, Hôpital NOVO

Phone: +330130754131

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hôpital NOVO
Registry
ClinicalTrials.gov
Start date
4 September 2025
Est. completion
31 March 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Assess whether the Optic Nerve Sheath Diameter (ONSD) measured by orbital ultrasound serves as an effective diagnostic marker for Giant Cell Arteritis (GCA)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov